Siegfried opens new global R&D Center for Drug Substances in Evionnaz
New facility to drive development excellence and further growth
Advertisement
Siegfried inaugurated its new global research and development (R&D) Center for Drug Substances at its site in Evionnaz, Switzerland. The 4,500m2 R&D Center houses advanced chemical and analytical facilities, state-of-the-art laboratories, and cutting-edge technologies such as flow chemistry, advanced distillation and process analytical technology, as well as new office space.
Together with the R&D Center in Zofingen, it will offer chemical process R&D and analytical development services for Siegfried’s global Drug Substances network. With workspaces for over 100 highly skilled specialists and 40 new jobs created, the R&D Center strengthens Siegfried’s development excellence in phase II and III supporting the company’s EVOLVE+ strategy.
Marcel Imwinkelried, CEO of Siegfried: “The new R&D Center in Evionnaz significantly enhances our Drug Substances network and demonstrates our unwavering commitment to providing cutting-edge research and development capabilities for our customers. It will be a key element in driving development excellence as part of our EVOLVE+ strategy and represents another pivotal step in strengthening our position among the top providers in the CDMO sector.”
Most read news
Other news from the department research and development
These products might interest you

KNAUER IJM NanoScaler by KNAUER
Efficient formulation of lipid nanoparticles for RNA-based therapies
Optimise drug encapsulation from 1 ml to hundreds of millilitres with minimal drug input

Pharmaceutical Substances by Thieme Verlag
Look up Industrial Syntheses of 2,600 APIs
Your tool for Syntheses, Patents and Applications – Pharmaceutical Substances

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

QUANTRO Therapeutics achieves breakthrough in transcriptomic drug discovery - First successful simultaneous 10-target multiplex-screening

BioMed X Institute launches new cancer collaboration with Daiichi Sankyo - Call for proposals from researchers around the world to take part in this ambitious project
CureVac enters clinical phase with mRNA vaccine - First data expected on intramuscular application of the newly developed vaccine

New drug candidates reverse drug resistance in multiple myeloma in preclinical models

Elevated hormone flags liver problems in mice with methylmalonic acidemia - Study findings can immediately be applied to human patients with the disease

Investigational monoclonal antibody to treat Ebola is safe in adults

NIH clinical trial of remdesivir to treat COVID-19 begins
APEIRON’s respiratory drug product to start pilot clinical trial to treat coronavirus disease

CORAT Therapeutics obtained regulatory authorization for clinical phase Ib/II trial with the SARS-CoV-2 neutralizing human antibody COR-101 - COR-101 is a human antibody that blocks virus infection by binding to the spike protein

New muscle therapy gets fast-track boost - Berlin start-up could soon be helping children with previously incurable muscle diseases thanks to an accelerated approval process

SAS accelerates delivery of novel medicines using AI and analytics - Cooperation with AstraZeneca for more innovation in clinical research
